

SIMPLIFIED CURRICULUM VITAE

PERSONAL BACKGROUND:

First name: Esteban

Surnames: Cano Jiménez

INVESTIGATOR ADDRESS:

Respiratory Medicine. Hospital Universitario Lucus Augusti (Lugo)

C/Ulises Romero n 1. 27003. Lugo. Spain.

EDUCATION:

Medicine, Universitat Autònoma de Barcelona , UD H. Vall d'Hebrón (2004)

POSTGRADUATE TRAINING:

+Respiratory medicine, Hospital Clínic de Barcelona, Spain (2009)

+Master in Biomedical research, Barcelona University. Spain (2010-2011)

+Master in Advances in diagnosis and treatment of the respiratory airways diseases, San Antonio Catholic University (UCAM) (2016-2018)

+Master in Interstitial Lung Diseases (UCAM) (2019-2020)

CLINICAL RESEARCH EXPERIENCE:

1. BIBF 1120 (Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II): Boehringer Ingelheim. BI 1199.34

2. MUSIC (Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study):. Actelion. ACT-064992

3. PIPF012 (Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis): InterMune.NCT00662038

4. ARTEMIS (Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF) : Gilead Sciences. NCT00768300

5. Efficacy and safety of SAR156597 in the treatment of idiopathic pulmonary fibrosis (ESTAIR). NCT2345070

6. GALACTIC-1 - A randomized, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks.

PROFESSIONAL EXPERIENCE:

❖ Previous appointments (List positions held, give dates and institutions):

- Respiratory medicine, Hospital Clínic de Barcelona (2009-2012)
- Researcher in the Insitute de investigaciones biomédicas Agustí Pi i Sunyer (IDIBAPS) (2010- 2012)

RESEARCH GRANTS:

1. FIS 2006: "Development of a new therapy to treat the idiopathic pulmonary fibrosis, based in the alveolar type II cells transplantation". Associated investigator.
2. FIS 2009: "Implicación del sistema angiotensina en la etiopatogenia de la fibrosis pulmonar idiopática". Associated investigator.
3. SOCAP 2010 "Esteve Teijin": "Regulation of angiotensin content in Idiopathic Pulmonary Fibrosis : metabolism and pathophysiological implications". Principal investigator.
4. FUCAP "Agustí Vidal" 2010: "Alveolar type II cells transplantation, derived from adult stem cells, for treatment of Idiopathic Pulmonary Fibrosis". Associated investigator.
5. SEPAR 2011: "Regulation of angiotensin converting enzyme in human alveolar type 2 cells culture". Principal investigator.
6. SEPAR 2011: "Regulation of angiotensin content in idiopathic pulmonary fibrosis: metabolism and pathophysiological implications". Principal investigator.

INDEXED MEDICAL PUBLICATIONS: 18

❖ Present appointment

- Respiratory Medicine, Hospital Universitario Lucus Augusti (Lugo). ILD Unit Coordinator.
- Researcher in the Integrated Investigation Project in Interstitial Lung Diseases (PII) of SEPAR (Spanish Respiratory Society).
- Coordinator emergent-ILD group in Spanish Respiratory Society